Caractérisation de l’utilisation du dioxyde de soufre et des sulfites dans les médicaments dispensés en France en 2022

Daphné Morel; Loïc Verlingue; Olivier Tillement; Eric Deutsch

doi:10.1684/jpc.2023.0526

Caractérisation de l’utilisation du dioxyde de soufre et des sulfites dans les médicaments dispensés en France en 2022

Translated title of the contribution: Sulfite derivatives use in french pharmaceutical products in 2022

Daphné Morel, Loïc Verlingue, Olivier Tillement, Eric Deutsch

Research output: Contribution to journal › Article › peer-review

Abstract

Sulfites are among the 37 excipients with a possible known effect listed by the French Health Autorities (ANSM) that can be found in French pharmaceutical registered drug. They are likely to cause severe hypersensitivity reactions and bronchospasm in intolerant patients. Guidelines on how to deal with sulfite hypersensitivity are limited to “avoidance of wines and products containing large amounts of sulfites”, without specifying the risk – if any – of prescribing and dispensing sulfite-containing medications.

Translated title of the contribution	Sulfite derivatives use in french pharmaceutical products in 2022
Original language	French
Pages (from-to)	109-118
Number of pages	10
Journal	Journal de Pharmacie Clinique
Volume	42
Issue number	3
DOIs	https://doi.org/10.1684/jpc.2023.0526
Publication status	Published - 1 Sept 2023

Access to Document

10.1684/jpc.2023.0526

Cite this

@article{fc6a3f683dce41deb3588d96c878402a,

title = "Caract{\'e}risation de l{\textquoteright}utilisation du dioxyde de soufre et des sulfites dans les m{\'e}dicaments dispens{\'e}s en France en 2022",

abstract = "Sulfites are among the 37 excipients with a possible known effect listed by the French Health Autorities (ANSM) that can be found in French pharmaceutical registered drug. They are likely to cause severe hypersensitivity reactions and bronchospasm in intolerant patients. Guidelines on how to deal with sulfite hypersensitivity are limited to “avoidance of wines and products containing large amounts of sulfites”, without specifying the risk – if any – of prescribing and dispensing sulfite-containing medications.",

keywords = "excipient intolerance, sulfite intolerance, sulfites",

author = "Daphn{\'e} Morel and Lo{\"i}c Verlingue and Olivier Tillement and Eric Deutsch",

note = "Publisher Copyright: {\textcopyright} 2023 John Libbey Eurotext.Tous droits r{\'e}serv{\'e}s.",

year = "2023",

month = sep,

day = "1",

doi = "10.1684/jpc.2023.0526",

language = "Fran{\c c}ais",

volume = "42",

pages = "109--118",

journal = "Journal de Pharmacie Clinique",

issn = "0291-1981",

number = "3",

}

TY - JOUR

T1 - Caractérisation de l’utilisation du dioxyde de soufre et des sulfites dans les médicaments dispensés en France en 2022

AU - Morel, Daphné

AU - Verlingue, Loïc

AU - Tillement, Olivier

AU - Deutsch, Eric

PY - 2023/9/1

Y1 - 2023/9/1

N2 - Sulfites are among the 37 excipients with a possible known effect listed by the French Health Autorities (ANSM) that can be found in French pharmaceutical registered drug. They are likely to cause severe hypersensitivity reactions and bronchospasm in intolerant patients. Guidelines on how to deal with sulfite hypersensitivity are limited to “avoidance of wines and products containing large amounts of sulfites”, without specifying the risk – if any – of prescribing and dispensing sulfite-containing medications.

AB - Sulfites are among the 37 excipients with a possible known effect listed by the French Health Autorities (ANSM) that can be found in French pharmaceutical registered drug. They are likely to cause severe hypersensitivity reactions and bronchospasm in intolerant patients. Guidelines on how to deal with sulfite hypersensitivity are limited to “avoidance of wines and products containing large amounts of sulfites”, without specifying the risk – if any – of prescribing and dispensing sulfite-containing medications.

KW - excipient intolerance

KW - sulfite intolerance

KW - sulfites

UR - http://www.scopus.com/inward/record.url?scp=85176397863&partnerID=8YFLogxK

U2 - 10.1684/jpc.2023.0526

DO - 10.1684/jpc.2023.0526

M3 - Article

AN - SCOPUS:85176397863

SN - 0291-1981

VL - 42

SP - 109

EP - 118

JO - Journal de Pharmacie Clinique

JF - Journal de Pharmacie Clinique

IS - 3

ER -

Caractérisation de l’utilisation du dioxyde de soufre et des sulfites dans les médicaments dispensés en France en 2022

Abstract

Access to Document

Other files and links

Cite this